AGP Executive Report
Last update: 10 hours agoNew Treatments: FDA approved Merck KGaA’s Pimjetmi for adults with symptomatic tenosynovial giant cell tumors when surgery could cause serious complications. Asundexian, the first approved factor XIa inhibitor, offers another option to prevent repeat strokes after certain ischemic strokes or high-risk TIAs. Cell and Gene Therapy: New FDA guidance urges manufacturers to build potency controls into every stage of development and production, not rely mainly on testing finished products. Manufacturing: Lonza will acquire five US drug-manufacturing sites from Merck KGaA, expanding its capacity for complex therapies and adding about 1,100 employees. Industry Pressures: Danaher’s Cepheid plans to cut 67 California jobs, mostly scientists and engineers. Meanwhile, the FDA has more than 1,000 vacancies, with staffing gaps affecting drug reviews. Mental Health: A large analysis found escitalopram performed well on average for depression, but researchers caution that no antidepressant works best for everyone.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
